Role of Inflammation in Suicide: From Mechanisms to Treatment

Neuropsychopharmacology

Volumn 42, Issue 1, 2017, Pages 271-283

  Brundin, Lena ^a   Bryleva, Elena Y ^a   Thirtamara Rajamani, Keerthi ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); HUMAN; INFECTION; INFLAMMATION; MENTAL DISEASE; META ANALYSIS (TOPIC); NEUROBIOLOGY; NEUROIMMUNOLOGY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUICIDE; SYMPTOM; TRAUMATIC BRAIN INJURY; VITAMIN D DEFICIENCY; DEPRESSION; IMMUNOLOGY; METABOLISM;

DEPRESSIVE DISORDER; HUMANS; INFLAMMATION; SUICIDE;

EID: 84979690565     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.116     Document Type: Review

References (186)

1. Alavi M, Grebely J, Matthews GV, Petoumenos K, Yeung B, Day C, et al. (2012). Effect of pegylated interferon-alpha-2a treatment on mental health during recenthepatitis C virus infection. J Gastroenterol Hepatol 27: 957-965.
2. Arinuma Y, Yanagida T, Hirohata S (2008). Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupuserythematosus. Arthritis Rheum 58: 1130-1135.
3. Arling TA, Yolken RH, Lapidus M, Langenberg P, Dickerson FB, Zimmerman SA, et al. (2009). Toxoplasma gondii antibody titers and history of suicide attempts inpatients with recurrent mood disorders. J Nerv Ment Dis 197: 905-908.
4. Arsenault-Lapierre G, Kim C, Turecki G (2004). Psychiatric diagnoses in 3275suicides: a meta-analysis. BMC Psychiatry 4: 37.
5. Bah TM, Kaloustian S, Rousseau G, Godbout R (2011). Pretreatment withpentoxifylline has antidepressant-like effects in a rat model of acute myocardialinfarction. Behav Pharmacol 22: 779-784.
6. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J (2006). Decreased risk of suicides and attempts during long-term lithium treatment:a meta-analytic review. Bipolar Disord 8: 625-639.
7. Bayard-Burfield L, Alling C, Blennow K, Jonsson S, Traskman-Bendz L (1996). Impairment of the blood-CSF barrier in suicide attempters. Eur Neuropsychopharmacol6: 195-199.
8. Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Traskman-Bendz L,Guillemin GJ, et al. (2015). A role for inflammatory metabolites as modulators of theglutamate N-methyl-D-aspartate receptor in depression and suicidality. BrainBehav Immun 43: 110-117.
9. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB(2011). Autoimmune diseases and severe infections as risk factors forschizophrenia: a 30-year population-based register study. Am J Psychiatry 168:1303-1310.
10. Bertolote JM, Fleischmann A, De Leo D, Phillips MR, Botega NJ, Vijayakumar L, et al. (2010). Repetition of suicide attempts: data from emergency care settings in fiveculturally different low-and middle-income countries participating in the WHOSUPRE-MISS Study. Crisis 31: 194-201.
11. Beurel E, Jope RS (2014). Inflammation and lithium: clues to mechanismscontributing to suicide-linked traits. Transl Psychiatry 4: e488.
12. Black C, Miller BJ (2015). Meta-analysis of cytokines and chemokines in suicidality:distinguishing suicidal versus nonsuicidal patients. Biol Psychiatry 78: 28-37.
13. Block ML, Hong JS (2005). Microglia and inflammation-mediated neurodegeneration:multiple triggers with a common mechanism. Prog Neurobiol 76: 77-98.
14. Brenner LA, Ignacio RV, Blow FC (2011). Suicide and traumatic brain injury amongindividuals seeking Veterans Health Administration services. J Head TraumaRehabil 26: 257-264.
15. Brent DA, Johnson BA, Perper J, Connolly J, Bridge J, Bartle S, et al. (1994). Personality disorder, personality traits, impulsive violence, and completed suicidein adolescents. J Am Acad Child Adolesc Psychiatry 33: 1080-1086.
16. Brent DA, Bridge J, Johnson BA, Connolly J (1996). Suicidal behavior runs infamilies. A controlled family study of adolescent suicide victims. Arch GenPsychiatry 53: 1145-1152.
17. Brezo J, Paris J, Vitaro F, Hebert M, Tremblay RE, Turecki G (2008). Predictingsuicide attempts in young adults with histories of childhood abuse. Br J Psychiatry193: 134-139.
18. Bronnum-Hansen H, Stenager E, Nylev Stenager E, Koch-Henriksen N (2005). Suicide among Danes with multiple sclerosis. J Neurol Neurosurg Psychiatry 76:1457-1459.
19. Busse M, Busse S, Myint AM, Gos T, Dobrowolny H, Muller UJ, et al. (2015). Decreased quinolinic acid in the hippocampus of depressive patients: evidencefor local anti-inflammatory and neuroprotective responses? Eur Arch PsychiatryClin Neurosci 265: 321-329.
20. Buter J, de Vries EG, Sleijfer DT, Willemse PH, Mulder NH (1993). Neuropsychiatricsymptoms during treatment with interleukin-2. Lancet 341: 628.
21. Canetto SS, Sakinofsky I (1998). The gender paradox in suicide. Suicide Life ThreatBehav 28: 1-23.
22. Capuron L, Ravaud A, Dantzer R (2000). Early depressive symptoms in cancerpatients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 18:2143-2151.
23. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH (2003). Association of exaggerated HPA axis response to the initial injection of interferonalphawith development of depression during interferon-alpha therapy. Am JPsychiatry 160: 1342-1345.
24. Capuron L, Ravaud A, Miller AH, Dantzer R (2004). Baseline mood andpsychosocial characteristics of patients developing depressive symptoms duringinterleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 18:205-213.
25. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, et al. (2002). Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind,placebo-controlled, dose-escalation trial. Arthritis Rheum 46: 3143-3150.
26. Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH (2002). Depressive symptoms and severity of illness in multiple sclerosis: epidemiologicstudy of a large community sample. Am J Psychiatry 159: 1862-1868.
27. Cippitelli M, Santoni A (1998). Vitamin D3: a transcriptional modulator of theinterferon-gamma gene. Eur J Immunol 28: 3017-3030.
28. Clark SM, Pocivavsek A, Nicholson JD, Notarangelo FM, Langenberg P,McMahon RP, et al. (2016). Reduced kynurenine pathway metabolism andcytokine expression in the prefrontal cortex of depressed individuals. J PsychiatryNeurosci 41: 150226.
29. Coccaro EF (2006). Association of C-reactive protein elevation with trait aggressionand hostility in personality disordered subjects: a pilot study. J Psychiatr Res 40:460-465.
30. Coccaro EF, Lee R, Coussons-Read M (2014). Elevated plasma inflammatorymarkers in individuals with intermittent explosive disorder and correlation withaggression in humans. JAMA Psychiatry 71: 158-165.
31. Cook TB, Brenner LA, Cloninger CR, Langenberg P, Igbide A, Giegling I, et al. (2015). 'Latent' infection with Toxoplasma gondii: association with trait aggression andimpulsivity in healthy adults. J Psychiatr Res 60: 87-94.
32. Crosby AE, Ortega L, Melanson C (2011). Self-directed Violence Surveillance:Uniform Definitions and Recommended Data Elements. Centers for DiseaseControl, Prevention, National Center for Injury Prevention and Control: Atlanta,GA, USA.
33. Cuomo C, Sarchiapone M, Giannantonio MD, Mancini M, Roy A (2008). Aggression,impulsivity, personality traits, and childhood trauma of prisoners with substanceabuse and addiction. Am J Drug Alcohol Abuse 34: 339-345.
34. Da Cruz D, Pearson A, Saini P, Miles C, While D, Swinson N, et al. (2011). Emergencydepartment contact prior to suicide in mental health patients. Emerg Med J 28:467-471.
35. Dahl J, Andreassen OA, Verkerk R, Malt UF, Sandvik L, Brundin L, et al. (2015). Ongoing episode of major depressive disorder is not associated with elevatedplasma levels of kynurenine pathway markers. Psychoneuroendocrinology 56:12-22.
36. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008). Frominflammation to sickness and depression: when the immune system subjugatesthe brain. Nat Rev Neurosci 9: 46-56.
37. Dantzer R, Walker AK (2014). Is there a role for glutamate-mediated excitotoxicity ininflammation-induced depression? J Neural Transm (Vienna) 121: 925-932.
38. de Carvalho LP, Bochet P, Rossier J (1996). The endogenous agonist quinolinic acidand the non endogenous homoquinolinic acid discriminate between NMDAR2receptor subunits. Neurochem Int 28: 445-452.
39. Dean OM, Maes M, Ashton M, Berk L, Kanchanatawan B, Sughondhabirom A, et al. (2014). Protocol and rationale-the efficacy of minocycline as an adjunctivetreatment for major depressive disorder: a double blind, randomised, placebocontrolled trial. Clin Psychopharmacol Neurosci 12: 180-188.
40. DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DAet al (2010). Rapid resolution of suicidal ideation after a single infusion of anN-methyl-D-aspartate antagonist in patients with treatment-resistant majordepressive disorder. J Clin Psychiatry 71: 1605-1611.
41. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring ML (2004). Suicidalideation during interferon-alpha2b and ribavirin treatment of patients with chronichepatitis C. Gen Hosp Psychiatry 26: 237-240.
42. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. (2010). A metaanalysisof cytokines in major depression. Biol Psychiatry 67: 446-457.
43. Dunn AJ (2000). Cytokine activation of the HPA axis. Ann NY Acad Sci 917:608-617.
44. Elgarf AS, Aboul-Fotouh S, Abd-Alkhalek HA, El Tabbal M, Hassan AN, Kassim SKet al (2014). Lipopolysaccharide repeated challenge followed by chronic mildstress protocol introduces a combined model of depression in rats: reversibility byimipramine and pentoxifylline. Pharmacol Biochem Behav 126: 152-162.
45. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, et al. (2013). Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology38: 743-752.
46. Ersozlu-Bozkirli ED, Keskek SO, Bozkirli E, Yucel AE (2015). The effect of infliximabon depressive symptoms in patients with ankylosing spondylitis. Acta ReumatolPort 40: 262-267.
47. Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, et al. (2012). Infliximab,a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: theimpact on depression, anxiety and quality of life level. Rheumatol Int 32: 323-330.
48. Falcone T, Fazio V, Lee C, Simon B, Franco K, Marchi N, et al. (2010). Serum S100B:a potential biomarker for suicidality in adolescents? PloS One 5: e11089.
49. Faridhosseini F, Sadeghi R, Farid L, Pourgholami M (2014). Celecoxib: a newaugmentation strategy for depressive mood episodes. A systematic review andmeta-analysis of randomized placebo-controlled trials. Human psychopharmacology29: 216-223.
50. Fazel S, Wolf A, Pillas D, Lichtenstein P, Langstrom N (2014). Suicide, fatal injuries,and other causes of premature mortality in patients with traumatic brain injury: a41-year Swedish population study. JAMA Psychiatry 71: 326-333.
51. Ferrari P, Mallon D, Trinder D, Olynyk JK (2010). Pentoxifylline improveshaemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology 15:344-349.
52. Fonseka TM, McIntyre RS, Soczynska JK, Kennedy SH (2015). Novel investigationaldrugs targeting IL-6 signaling for the treatment of depression. Expert Opin InvestigDrugs 24: 459-475.
53. Fragoso-Loyo H, Cabiedes J, Orozco-Narvaez A, Davila-Maldonado L, Atisha-Fregoso Y, Diamond B, et al. (2008). Serum and cerebrospinal fluid autoantibodiesin patients with neuropsychiatric lupus erythematosus. Implications for diagnosisand pathogenesis. PloS One 3: e3347.
54. Fragoso YD, Frota ER, Lopes JS, Noal JS, Giacomo MC, Gomes S, et al. (2010). Severe depression, suicide attempts, and ideation during the use of interferonbeta by patients with multiple sclerosis. Clin Neuropharmacol 33: 312-316.
55. Fredrikson S, Cheng Q, Jiang GX, Wasserman D (2003). Elevated suicide riskamong patients with multiple sclerosis in Sweden. Neuroepidemiology 22:146-152.
56. Freudenberg F, Celikel T, Reif A (2015). The role of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: centralmediators of pathophysiology and antidepressant activity? Neurosci BiobehavRev 52: 193-206.
57. Gabbay V, Klein RG, Guttman LE, Babb JS, Alonso CM, Nishawala M, et al. (2009). A preliminary study of cytokines in suicidal and nonsuicidal adolescents with majordepression. J Child Adolesc Psychopharmacol 19: 423-430.
58. Gaskell EA, Smith JE, Pinney JW, Westhead DR, McConkey GA (2009). A uniquedual activity amino acid hydroxylase in Toxoplasma gondii. PloS One 4: e4801.
59. Gazzinelli R, Xu YH, Hieny S, Cheever A, Sher A (1992). Simultaneous depletion ofCd4+ and Cd8+ lymphocytes-T is required to reactivate chronic infection withToxoplasma gondii. J Immunol 149: 175-180.
60. Gelfand JM, Kimball AB, Mostow EN, Chiou CF, Patel V, Xia HA, et al. (2008). Patientreportedoutcomes and health-care resource utilization in patients with psoriasistreated with etanercept: continuous versus interrupted treatment. Value Health11: 400-407.
61. Ghanizadeh A, Baligh-Jahromi P (2009). Depression, anxiety and suicidal behaviourin children and adolescents with Haemophilia. Haemophilia 15: 528-532.
62. Ghanizadeh A, Khajavian S, Ashkani H (2006). Prevalence of psychiatric disorders,depression, and suicidal behavior in child and adolescent with thalassemia major. J Pediatr Hematol Oncol 28: 781-784.
63. Gono T, Kawaguchi Y, Kaneko H, Nishimura K, Hanaoka M, Kataoka S, et al. (2011). Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupuserythematosus. Rheumatology 50: 1578-1585.
64. Gonzalez-Espinoza L, Rojas-Campos E, Medina-Perez M, Pena-Quintero P,Gomez-Navarro B, Cueto-Manzano AM (2012). Pentoxifylline decreases serumlevels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein inhemodialysis patients: results of a randomized double-blind, controlledclinical trial. Nephrol Dial Transplant 27: 2023-2028.
65. Grudet C, Malm J, Westrin A, Brundin L (2014). Suicidal patients are deficient invitamin D, associated with a pro-inflammatory status in the blood. Psychoneuroendocrinology50: 210-219.
66. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ (2007). Lithium treatment reducessuicide risk in recurrent major depressive disorder. J Clin Psychiatry 68: 380-383.
67. Hanke ML, Kielian T (2011). Toll-like receptors in health and disease in the brain:mechanisms and therapeutic potential. Clin Sci 121: 367-387.
68. Henriquez SA, Brett R, Alexander J, Pratt J, Roberts CW (2009). Neuropsychiatricdisease and Toxoplasma gondii infection. Neuroimmunomodulation 16: 122-133.
69. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX(2001). The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptoractivity and increases non-alpha7 nicotinic receptor expression: physiopathologicalimplications. J Neurosci 21: 7463-7473.
70. Howren MB, Lamkin DM, Suls J (2009). Associations of depression with C-reactiveprotein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71: 171-186.
71. Huang TL, Lee CT (2007). T-helper 1/T-helper 2 cytokine imbalance and clinicalphenotypes of acute-phase major depression. Psychiatry Clin Neurosci 61:415-420.
72. Husain MI, Chaudhry IB, Rahman RR, Hamirani MM, Qurashi I, Khoso AB, et al. (2015). Minocycline as an adjunct for treatment-resistant depressive symptoms:study protocol for a pilot randomised controlled trial. Trials 16: 410.
73. Ishikura R, Morimoto N, Tanaka K, Kinukawa N, Yoshizawa S, Horiuchi T, et al. (2001). Factors associated with anxiety, depression and suicide ideation in femaleoutpatients with SLE in Japan. Clin Rheumatol 20: 394-400.
74. Isung J, Aeinehband S, Mobarrez F, Martensson B, Nordstrom P, Asberg M, et al. (2012). Low vascular endothelial growth factor and interleukin-8 in cerebrospinalfluid of suicide attempters. Transl Psychiatry 2: e196.
75. Isung J, Aeinehband S, Mobarrez F, Nordstrom P, Runeson B, Asberg M, et al. (2014). High interleukin-6 and impulsivity: determining the role of endophenotypesin attempted suicide. Transl Psychiatry 4: e470.
76. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. (2004). A pilotrandomized trial of a human anti-interleukin-6 receptor monoclonal antibody inactive Crohn's disease. Gastroenterology 126: 989-996.
77. Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L (2011). Cytokinelevels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun 25: 335-339.
78. Janelidze S, Suchankova P, Ekman A, Erhardt S, Sellgren C, Samuelsson M, et al. (2015). Low IL-8 is associated with anxiety in suicidal patients: genetic variationand decreased protein levels. Acta Psychiatr Scand 131: 269-278.
79. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW (1994). Suicide associatedwith alfa-interferon therapy for chronic viral hepatitis. J Hepatol 21: 241-243.
80. Juengst SB, Kumar RG, Arenth PM, Wagner AK (2014). Exploratory associationswith tumor necrosis factor-alpha, disinhibition and suicidal endorsement aftertraumatic brain injury. Brain Behav Immun 41: 134-143.
81. Kim YK, Lee SW, Kim SH, Shim SH, Han SW, Choi SH, et al. (2008). Differences incytokines between non-suicidal patients and suicidal patients in major depression. Prog Neuropsychopharmacol Biol Psychiatry 32: 356-361.
82. Liu Y, Ho RC, Mak A (2012). Interleukin (IL)-6, tumour necrosis factor alpha(TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patientswith major depressive disorder: a meta-analysis and meta-regression. J AffectDisord 139: 230-239.
83. Kim H, Chen L, Lim G, Sung B, Wang S, McCabe MF, et al. (2012). Brain indoleamine2,3-dioxygenase contributes to the comorbidity of pain and depression. J ClinInvest 122: 2940-2954.
84. Kim JW, Szigethy EM, Melhem NM, Saghafi EM, Brent DA (2014). Inflammatorymarkers and the pathogenesis of pediatric depression and suicide: a systematicreview of the literature. J Clin Psychiatry 75: 1242-1253.
85. Kjaergaard M, Joakimsen R, Jorde R (2011). Low serum 25-hydroxyvitamin D levelsare associated with depression in an adult Norwegian population. Psychiatry Res190: 221-225.
86. Labonte B, Suderman M, Maussion G, Lopez JP, Navarro-Sanchez L, Yerko V, et al. (2013). Genome-wide methylation changes in the brains of suicide completers. Am J Psychiatry 170: 511-520.
87. Labonte B, Suderman M, Maussion G, Navaro L, Yerko V, Mahar I, et al. (2012). Genome-wide epigenetic regulation by early-life trauma. Arch Gen Psychiatry 69:722-731.
88. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, et al. (2006). Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, anddepression in systemic lupus erythematosus. Arthritis Rheum 54: 2505-2514.
89. Larkin GL, Beautrais AL (2011). A preliminary naturalistic study of low-dose ketaminefor depression and suicide ideation in the emergency department. Int JNeuropsychopharmacol 14: 1127-1131.
90. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. (2009). Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and relatedto symptom severity. Biol Psychiatry 66: 287-292.
91. Ling VJ, Lester D, Mortensen PB, Langenberg PW, Postolache TT (2011). Toxoplasma gondii Seropositivity and Suicide Rates in Women. J Nerv MentDis 199: 440-444.
92. Lucaciu LA, Dumitrascu DL (2015). Depression and suicide ideation in chronichepatitis C patients untreated and treated with interferon: prevalence, prevention,and treatment. Ann Gastroenterol 28: 440-447.
93. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R (2011). The new '5-HT'hypothesis of depression: cell-mediated immune activation induces indoleamine2,3-dioxygenase, which leads to lower plasma tryptophan and an increasedsynthesis of detrimental tryptophan catabolites (TRYCATs), both of whichcontribute to the onset of depression. Prog Neuropsychopharmacol BiolPsychiatry 35: 702-721.
94. Mackay GM, Forrest CM, Stoy N, Christofides J, Egerton M, Stone TW, et al. (2006). Tryptophan metabolism and oxidative stress in patients with chronic brain injury. Eur J Neurol 13: 30-42.
95. Mackelprang JL, Bombardier CH, Fann JR, Temkin NR, Barber JK, Dikmen SS(2014). Rates and predictors of suicidal ideation during the first year aftertraumatic brain injury. Am J Public Health 104: e100-e107.
96. Mandi Y, Vecsei L (2012). The kynurenine system and immunoregulation. J NeuralTransm (Vienna) 119: 197-209.
97. Mann JJ (2003). Neurobiology of suicidal behaviour. Nat Rev Neurosci 4: 819-828.
98. McGirr A, Renaud J, Bureau A, Seguin M, Lesage A, Turecki G (2008). Impulsiveaggressivebehaviours and completed suicide across the life cycle: a predispositionfor younger age of suicide. Psychological Med 38: 407-417.
99. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, et al. (2009). Epigenetic regulation of the glucocorticoid receptor in human brain associateswith childhood abuse. Nat Neurosci 12: 342-348.
100. Mendlovic S, Mozes E, Eilat E, Doron A, Lereya J, Zakuth V, et al. (1999). Immuneactivation in non-treated suicidal major depression. Immunol Lett 67: 105-108.
101. Meyers CA, Scheibel RS, Forman AD (1991). Persistent neurotoxicity of systemicallyadministered interferon-alpha. Neurology 41: 672-676.
102. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011). Meta-analysis ofcytokine alterations in schizophrenia: clinical status and antipsychotic effects. BiolPsychiatry 70: 663-671.
103. Miller CM, Boulter NR, Ikin RJ, Smith NC (2009). The immunobiology of the innateresponse to Toxoplasma gondii. Int J Parasitol 39: 23-39.
104. Minderhoud IM, Samsom M, Oldenburg B (2007). Crohn's disease, fatigue, andinfliximab: is there a role for cytokines in the pathogenesis of fatigue? World JGastroenterol 13: 2089-2093.
105. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K (1999). Depressionfrom interferon therapy in patients with hepatitis C. Am J Psychiatry 156: 1120.
106. Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, et al. (2012). Minocycline as adjunctive therapy for patients with unipolar psychotic depression:an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 37: 222-226.
107. Mommersteeg PM, Vermetten E, Kavelaars A, Geuze E, Heijnen CJ (2008). Hostilityis related to clusters of T-cell cytokines and chemokines in healthy men. Psychoneuroendocrinology 33: 1041-1050.
108. Moscicki EK (1994). Gender differences in completed and attempted suicides. AnnEpidemiol 4: 152-158.
109. Mossner R, Heils A, Stober G, Okladnova O, Daniel S, Lesch KP (1998). Enhancement of serotonin transporter function by tumor necrosis factor alphabut not by interleukin-6. Neurochem Int 33: 251-254.
110. Munkholm K, Brauner JV, Kessing LV, Vinberg M (2013). Cytokines in bipolardisorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 47: 1119-1133.
111. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B (2007). Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 98: 143-151.
112. Myint AM, Schwarz MJ, Muller N (2012). The role of the kynurenine metabolism inmajor depression. J Neural Transm (Vienna) 119: 245-251.
113. Na KS, Lee KJ, Lee JS, Cho YS, Jung HY (2014). Efficacy of adjunctive celecoxibtreatment for patients with major depressive disorder: a meta-analysis. ProgNeuropsychopharmacol Biol Psychiatry 48: 79-85.
114. Nassberger L, Traskman-Bendz L (1993). Increased soluble interleukin-2 receptorconcentrations in suicide attempters. Acta Psychiatr Scand 88: 48-52.
115. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, et al. (2008). Celecoxib as an adjunct in the treatment of depressive or mixed episodes ofbipolar disorder: a double-blind, randomized, placebo-controlled study. HumPsychopharmacol 23: 87-94.
116. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grunwald C, et al. (1994). Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 83: 262-267.
117. Notarangelo FM, Wilson EH, Horning KJ, Thomas MA, Harris TH, Fang Q, et al. (2014). Evaluation of kynurenine pathway metabolism in Toxoplasma gondiiinfectedmice: implications for schizophrenia. Schizophr Res 152: 261-267.
118. O'Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N, et al. (2009). Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine2,3-dioxygenase activation in mice. Mol Psychiatry 14: 511-522.
119. O'Donovan A, Rush G, Hoatam G, Hughes BM, McCrohan A, Kelleher C, et al. (2013). Suicidal ideation is associated with elevated inflammation in patients withmajor depressive disorder. Depress Anxiety 30: 307-314.
120. Okun E, Griffioen K, Barak B, Roberts NJ, Castro K, Pita MA, et al. (2010). Toll-likereceptor 3 inhibits memory retention and constrains adult hippocampalneurogenesis. Proc Natl Acad Sci USA 107: 15625-15630.
121. Okun E, Griffioen KJ, Mattson MP (2011). Toll-like receptor signaling in neuralplasticity and disease. Trends Neurosci 34: 269-281.
122. Okusaga O, Yolken RH, Langenberg P, Lapidus M, Arling TA, Dickerson FB, et al. (2011). Association of seropositivity for influenza and coronaviruses with history ofmood disorders and suicide attempts. J Affect Disord 130: 220-225.
123. Oquendo MA, Sullivan GM, Sudol K, Baca-Garcia E, Stanley BH, Sublette ME, et al. (2014). Toward a biosignature for suicide. Am J Psychiatry 171: 1259-1277.
124. Palagini L, Mosca M, Tani C, Gemignani A, Mauri M, Bombardieri S (2013). Depression and systemic lupus erythematosus: a systematic review. Lupus 22:409-416.
125. Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC, et al. (2012). Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res 46: 57-63.
126. Pandey GN, Rizavi HS, Ren X, Bhaumik R, Dwivedi Y (2014). Toll-like receptors inthe depressed and suicide brain. J Psychiatr Res 53: 62-68.
127. Perez-Otano I, Schulteis CT, Contractor A, Lipton SA, Trimmer JS, Sucher NJ, et al. (2001). Assembly with the NR1 subunit is required for surface expression ofNR3A-containing NMDA receptors. J Neurosci 21: 1228-1237.
128. Pollice PF, Rosier RN, Looney RJ, Puzas JE, Schwarz EM, O'Keefe RJ (2001). Oralpentoxifylline inhibits release of tumor necrosis factor-alpha from humanperipheral blood monocytes: a potential treatment for aseptic loosening of totaljoint components. J Bone Joint Surg Am 83-A: 1057-1061.
129. Prandovszky E, Gaskell E, Martin H, Dubey JP, Webster JP, McConkey GA (2011). The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. PloS One 6: e23866.
130. Price RB, Mathew SJ (2015). Does ketamine have anti-suicidal properties? Currentstatus and future directions. CNS Drugs 29: 181-188.
131. Price RB, Nock MK, Charney DS, Mathew SJ (2009). Effects of intravenousketamine on explicit and implicit measures of suicidality in treatment-resistantdepression. Biol Psychiatry 66: 522-526.
132. Price RK, Risk NK, Haden AH, Lewis CE, Spitznagel EL (2004). Post-traumaticstress disorder, drug dependence, and suicidality among male Vietnamveterans with a history of heavy drug use. Drug Alcohol Depend 76 Suppl:S31-S43.
133. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab fortreatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70: 31-41.
134. Ramamoorthy S, Ramamoorthy JD, Prasad PD, Bhat GK, Mahesh VB, Leibach FHet al (1995). Regulation of the human serotonin transporter by interleukin-1 beta. Biochem Biophys Res Commun 216: 560-567.
135. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, et al. (1987). Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med147: 1577-1580.
136. Reus GZ, Jansen K, Titus S, Carvalho AF, Gabbay V, Quevedo J (2015). Kynureninepathway dysfunction in the pathophysiology and treatment of depression:Evidences from animal and human studies. J Psychiatr Res 68: 316-328.
137. Roth TL, Zoladz PR, Sweatt JD, Diamond DM (2011). Epigenetic modification ofhippocampal Bdnf DNA in adult rats in an animal model of post-traumatic stressdisorder. J Psychiatr Res 45: 919-926.
138. Roy A (2003). Characteristics of drug addicts who attempt suicide. Psychiatry Res121: 99-103.
139. Sadovnick AD, Eisen K, Ebers GC, Paty DW (1991). Cause of death in patientsattending multiple sclerosis clinics. Neurology 41: 1193-1196.
140. Savitz J, Preskorn S, Teague TK, Drevets D, Yates W, Drevets W (2012). Minocyclineand aspirin in the treatment of bipolar depression: a protocol for a proof-ofconcept,randomised, double-blind, placebo-controlled, 2x2 clinical trial. BMJOpen 2: e000643.
141. Schnieder TP, Trencevska I, Rosoklija G, Stankov A, Mann JJ, Smiley J, et al. (2014). Microglia of prefrontal white matter in suicide. J Neuropathol Exp Neurol 73:880-890.
142. Schwarcz R, Bruno JP, Muchowski PJ,Wu HQ (2012). Kynurenines in the mammalianbrain: when physiology meets pathology. Nat Rev Neurosci 13: 465-477.
143. Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, et al. (2015). Increased levels of IL-6 in the cerebrospinal fluid of patients with chronicschizophrenia-significance for activation of the kynurenine pathway. J PsychiatryNeurosci 40: 126-133.
144. Serafini G, Montebovi F, Lamis DA, Erbuto D, Girardi P, Amore M, et al. (2015). Associations among depression, suicidal behavior, and quality of life in patientswith human immunodeficiency virus. World J Virol 4: 303-312.
145. Simanek AM, Cheng C, Yolken R, Uddin M, Galea S, Aiello AE (2014). Herpesviruses, inflammatory markers and incident depression in a longitudinalstudy of Detroit residents. Psychoneuroendocrinology 50: 139-148.
146. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B (2014). Sirukumab, a humananti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-conceptand dose-finding), phase II study in patients with active rheumatoid arthritisdespite methotrexate therapy. Ann Rheum Dis 73: 1616-1625.
147. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. (2008). Immunologicalaspects in the neurobiology of suicide: elevated microglial density in schizophreniaand depression is associated with suicide. J Psychiatr Res 42: 151-157.
148. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, et al. (2011). Severe depression is associated with increased microglial quinolinic acid insubregions of the anterior cingulate gyrus: evidence for an immune-modulatedglutamatergic neurotransmission? J Neuroinflammation 8: 94.
149. Steptoe A(ed) (2007). Depression and Physical Illness. Cambridge University Press:Cambridge.
150. Stone TW (1993). Neuropharmacology of quinolinic and kynurenic acids. PharmacolRev 45: 309-379.
151. Suarez EC, Lewis JG, Kuhn C (2002). The relation of aggression, hostility, and angerto lipopolysaccharide-stimulated tumor necrosis factor (TNF)-alpha by bloodmonocytes from normal men. Brain Behav Immun 16: 675-684.
152. Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA, et al. (2011). Plasma kynurenine levels are elevated in suicide attempters with majordepressive disorder. Brain Behav Immun 25: 1272-1278.
153. Substance Abuse and Mental Health Services Administration. Results from the 2013National Survey on Drug Use and Health: Mental Health Findings, NSDUH SeriesH-49, HHS Publication No. (SMA) 14-4887. Substance Abuse and Mental HealthServices: Rockville, MD, 2014. Available at http://www. samhsa. gov/data/sites/default/files/NSDUHmhfr2013/NSDUHmhfr2013.pdf.
154. pdf. Tanaka Y, Martin Mola E (2014). IL-6 targeting compared to TNF targeting inrheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. AnnRheum Dis 73: 1595-1597.
155. Tavares RG, Tasca CI, Santos CE, Alves LB, Porciuncula LO, Emanuelli T, et al. (2002). Quinolinic acid stimulates synaptosomal glutamate release and inhibitsglutamate uptake into astrocytes. Neurochem Int 40: 621-627.
156. Taylor MW, Feng GS (1991). Relationship between interferon-gamma, indoleamine2,3-dioxygenase, and tryptophan catabolism. FASEB J 5: 2516-2522.
157. Tidemalm D, Runeson B, Waern M, Frisell T, Carlstrom E, Lichtenstein P, et al. (2011). Familial clustering of suicide risk: a total population study of 11. 4 millionindividuals. Psychol Med 41: 2527-2534.
158. Tonelli LH, Stiller J, Rujescu D, Giegling I, Schneider B, Maurer K, et al. (2008). Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. ActaPsychiatr Scand 117: 198-206.
159. Tookman AJ, Jones CL, DeWitte M, Lodge PJ (2008). Fatigue in patients withadvanced cancer: a pilot study of an intervention with infliximab. Support CareCancer 16: 1131-1140.
160. Torres-Platas SG, Cruceanu C, Chen GG, Turecki G, Mechawar N (2014). Evidence for increased microglial priming and macrophage recruitment in thedorsal anterior cingulate white matter of depressed suicides. Brain Behav Immun42: 50-59.
161. Treatment. CfSA (2009). Addressing Suicidal Thoughts and Behaviors in SubstanceAbuse Treatment. HHS Publication No. (SMA): Rockville, MD, USA, 09-4381.
162. Umhau JC, George DT, Heaney RP, Lewis MD, Ursano RJ, Heilig M, et al. (2013). Low vitamin D status and suicide: a case-control study of active duty militaryservice members. PloS One 8: e51543.
163. Urata Y, Koga K, Hirota Y, Akiyama I, Izumi G, Takamura M, et al. (2014). IL-1beta increases expression of tryptophan 2,3-dioxygenase and stimulatestryptophan catabolism in endometrioma stromal cells. Am J Reprod Immunol 72:496-503.
164. US National Institute of Health (2016). Clinical trials. Available at https://clinicaltrials. gov/.
165. Valkanova V, Ebmeier KP, Allan CL (2013). CRP, IL-6 and depression: a systematicreview and meta-analysis of longitudinal studies. J Affect Disord 150: 736-744.
166. Vaswani M, Linda FK, Ramesh S (2003). Role of selective serotonin reuptakeinhibitors in psychiatric disorders: a comprehensive review. Prog NeuropsychopharmacolBiolog Psychiatry 27: 85-102.
167. Ventorp F, Barzilay R, Erhardt S, Samuelsson M, Traskman-Bendz L, Janelidze Set al (2016). The CD44 ligand hyaluronic acid is elevated in the cerebrospinal fluidof suicide attempters and is associated with increased blood-brain barrierpermeability. J Affect Disord 193: 349-354.
168. Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B, et al. (2013). NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induceddepressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 38:1609-1616.
169. Wekking EM (1993). Psychiatric symptoms in systemic lupus erythematosus:an update. Psychosoma Medicine 55: 219-228.
170. WHO (2012). Disease and injury regional mortality estimates, 2000-2012.
171. WHO (2014). Preventing Suicide: A Global Imperative. World Health Organization.
172. Wilcox HC, Conner KR, Caine ED (2004). Association of alcohol and drug usedisorders and completed suicide: an empirical review of cohort studies. DrugAlcohol Depend 76 Suppl: S11-S19.
173. Wohleb ES, Powell ND, Godbout JP, Sheridan JF (2013). Stress-inducedrecruitment of bone marrow-derived monocytes to the brain promotes anxietylikebehavior. J Neurosci 33: 13820-13833.
174. World Health Organization. (2011). Projections of mortality and causes of death,2015 and 2030.
175. Wu MK, Huang TL, Huang KW, Huang YL, Hung YY (2015). Association betweentoll-like receptor 4 expression and symptoms of major depressive disorder. Neuropsychiatr Dis Treat 11: 1853-1857.
176. Xie LF, Chen PL, Pan HF, Tao JH, Li XP, Zhang YJ, et al. (2012). Prevalence andcorrelates of suicidal ideation in SLE inpatients: Chinese experience. RheumatolInt 32: 2707-2714.
177. Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, et al. (2000). Illness,cztokines, and depression. Ann NY Acad Sci 917: 478-487.
178. Yoshio T, Onda K, Nara H, Minota S (2006). Association of IgG anti-NR2 glutamatereceptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupuserythematosus. Arthritis Rheum 54: 675-678.
179. Zakeri Z, Shakiba M, Narouie B, Mladkova N, Ghasemi-Rad M, Khosravi A (2012). Prevalence of depression and depressive symptoms in patients with systemiclupus erythematosus: Iranian experience. Rheumatol Int 32: 1179-1187.
180. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533: 481-486.
181. Zanos P, Piantadosi SC, Wu HQ, Pribut HJ, Dell MJ, Can A, et al. (2015). Theprodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, butnot side effects, by NMDA/glycineb-site inhibition. J Pharmacol Exp Ther 355:76-85.
182. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N,Cravchik A, et al. (2012). Replication of ketamine's antidepressant efficacy inbipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71:939-946.
183. Zhang J, Terreni L, De Simoni MG, Dunn AJ (2001). Peripheral interleukin-6administration increases extracellular concentrations of serotonin and the evokedrelease of serotonin in the rat striatum. Neurochem Int 38: 303-308.
184. Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW, et al. (2012). VitaminD inhibits monocyte/macrophage proinflammatory cytokine production bytargeting MAPK phosphatase-1. J Immunol 188: 2127-2135.
185. Zhu CB, Blakely RD, Hewlett WA (2006). The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology31: 2121-2131.
186. Zhu CB, Carneiro AM, Dostmann WR, Hewlett WA, Blakely RD (2005). p38 MAPKactivation elevates serotonin transport activity via a trafficking-independent,protein phosphatase 2A-dependent process. J Biol Chem 280: 15649-15658.